Efficacy of Prophylactic Antibiotics in Bakri Intrauterine Balloon Placement: A Single-Center Retrospective Analysis and Literature Review

Yoshikazu Nagase, MD1 Shinya Matsuzaki, MD, PhD1 Yoko Kawanishi, MD1 Satoshi Nakagawa, MD, PhD1 Aiko Kakigano, MD, PhD1 Tsuyoshi Takiuchi, MD, PhD1 Kazuya Mimura, MD1 Takju Tomimatsu, MD, PhD1 Masayuki Endo, MD, PhD1,2 Tadashi Kimura, MD, PhD1

1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan 2Department of Children and Women’s Health, Osaka University Graduate School of Medicine, Osaka, Japan

Address for correspondence Aiko Kakigano, MD, PhD, Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan (e-mail: ai-kaki@gyne.med.osaka-u.ac.jp).

Am J Perinatol Rep 2020;10:e106–e112.

Abstract

Objective Bakri intrauterine balloon (BIUB) placement is an effective treatment for postpartum hemorrhage (PPH). This study aims to evaluate the risk of infection during BIUB placement.

Study Design Data for all deliveries (n = 2,144) at our institution between January 2014 and March 2018 were retrospectively reviewed. Patients diagnosed with PPH (n = 758) were included in our analysis, further divided into BIUB (n = 80) and non-BIUB groups (n = 678), and subdivided into vaginal delivery (VD), elective cesarean delivery (CD), and emergency CD groups. Postpartum endometritis rate was compared in each group. A single dose of prophylactic antibiotics was administered for BIUB placement in the VD group. In the CD groups, antibiotics were administered preoperatively once, and no additional antibiotics for BIUB placement were administered. To obtain an antibiotics administration protocol to be applied during BIUB placement, we electronically searched the PubMed and Scopus databases.

Results No significant differences were observed in endometritis rates between BIUB and non-BIUB groups of all groups. In the literature review, of 27 suitable publications identified, multiple doses of antibiotics were administered in 17 (62.9%) studies and none investigated the efficacy of a protocol for antibiotic.

Conclusion Our protocol might be effective and sufficient in preventing postpartum BIUB placement-related endometritis.

Keywords

► Bakri balloon
► balloon tamponade
► complication
► endometritis
► prophylactic antibiotics
► postpartum hemorrhage

Postpartum hemorrhage (PPH) is a leading cause of maternal death.1 Treatment strategies include the use of uterotonics (e.g., oxytocin), intrauterine balloon tamponade, uterine compression sutures, interventional radiology, uterine artery ligation, and hysterectomy.1–3 Bakri first described the effectiveness of intrauterine balloon tamponade for the treatment of PPH during cesarean delivery (CD) in patients with low-lying placentas in 1992.6 Since then, various methods of intrauterine balloon tamponade have been proposed and have yielded good outcomes, with hemostasis rates generally exceeding 80%.7–11

The Bakri intrauterine balloon (BIUB; Cook Medical, Bloomington, IN) is a uterine-specific tamponade balloon with proven effectiveness.12,13 Although some authors have indicated that balloon placement can cause infection,14,15 the
infection rates among women requiring BIUBs have never been described, and little is known about the benefit of prophylactic antibiotic protocols.

The aim of the present study was to evaluate the risk of infection, particularly endometritis, and the effectiveness of a prophylactic antibiotic protocol. It was expected to provide useful information to obstetricians who use BIUB for PPH.

Materials and Methods

Study Design

In this retrospective analysis, we reviewed data from the deliveries at Osaka University Hospital, Osaka, Japan, between January 2014 and March 2018. The study was approved by the Osaka University Ethics Committee (approval 18130, approved on August 1, 2018). Informed consent was not required from patients because of the retrospective nature of the analysis, which was based on computerized data and anonymous selection criteria.

Patients diagnosed with PPH who had cumulative blood loss greater than or equal to 1,000 mL according to the American College of Obstetricians and Gynecologists (ACOG) definition were primarily divided into BIUB and non-BIUB groups, and were further divided into vaginal delivery (VD), elective CD (el-CD), and emergency CD (em-CD) groups.

Among these, we evaluated the following clinical characteristics and outcomes: maternal age at delivery, gravidity and parity, length of pregnancy at delivery, status of Group B Streptococcus (GBS) in vaginal swab within 4 weeks of delivery, rate of premature membrane rupture, percentage using an intrauterine pressure catheter, rate of manual removal of placenta, indication for CD groups only, total blood loss during delivery, rate of blood transfusion, rate of chorioamnionitis (CAM), time from delivery to BIUB placement, blood loss from delivery to BIUB placement, BIUB volume, blood loss duration during BIUB placement, duration of BIUB placement, and additional surgical treatments used to control PPH. We defined CAM as being confirmed by histopathological analysis in this study. We excluded patients who were administered antibiotics in a manner different to our protocol, together with patients diagnosed with CAM.

Procedures

Our protocol for antibiotic prophylaxis in cases requiring BIUB is shown in Fig. 1. In the VD group, we administered a single dose of prophylactic antibiotics (e.g., ampicillin 2 g or cefazolin 1 g) intravenously before BIUB insertion. In the CD groups, we administered antibiotics (e.g., ampicillin 2 g or cefazolin 1 g) preoperatively once, and no additional antibiotics were administered unless intraoperative bleeding.

![Diagram](image_url)

**Fig. 1** Prophylactic antibiotic protocol used in this study. \(^1\) In the VD group, a single prophylactic dose of antibiotic was administered before balloon insertion, aiming to prevent endometritis due to BIUB placement. \(^1\) In the CD groups, antibiotics were administered preoperatively and when blood loss exceeded 1,500 mL, consistent with the aim to decrease surgical site infection, regardless of whether the BIUB was placed. No additional antibiotics were administered in either group after the procedure if there were no signs of infection. BIUB, Bakri intrauterine balloon; CD, cesarean delivery; VD, vaginal delivery.
Excluded. The search strategy included the keywords specific to Bakri balloon in each database. We did not add any antibiotics regardless of BIUB placement in CD cases. In all groups, no additional antibiotics were given during BIUB placement unless there were signs of infection.

The BIUB was placed transvaginally through the cervix in VD cases and transabdominally through the cesarean uterine incision in some CD cases. Gauze was packed into the vagina to prevent prolapse of the BIUB from the uterus in all cases. If bleeding was controlled after balloon inflation, the balloon tamponade was kept in place for 12 to 24 hours.

Postpartum endometritis was defined as fever >38°C beginning >24 hours or continuing at least 24 hours after delivery plus fundal tenderness, with no other recognized cause of fever, according to the definition of the Centers for Disease Control and Prevention (CDC).16

Outcomes
The primary outcome was to determine the postpartum endometritis rate comparing those cases with BIUB and non-BIUB in each group. The secondary outcome was to investigate the rates of other complications, such as uterine perforation and cervical trauma, caused by BIUB placement.

Literature Review
We performed a literature review to discuss the effectiveness of prophylactic antibiotic use in women requiring a BIUB. This involved an electronic search of the PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and Scopus (https://www.scopus.com) databases from April 1992 to August 2018 with some modification of the previous method.17,18 Review articles and articles in languages other than English were excluded. The search strategy included the keywords specific to Bakri balloon in each database.

The search strategy used keywords that were specific to each database and included the following terms: “Bakri balloon,” “antibiotics,” “PPH,” “endometritis,” or “infection.” The keywords were used in various combinations. All articles referring to Bakri balloons were screened, and we excluded studies that did not describe antibiotic use. A flow diagram of the literature search is presented in Supplementary Material S1 (available online only).

Statistical Analysis
We performed the statistical analysis using JMP Pro version 14.0.0 (SAS Institute, Cary, NC). Continuous variables were analyzed using the t-test, and categorical variables were analyzed using Chi-square test or Fisher’s exact test. A p value of <0.05 indicated statistical significance.

Results
Retrospective Study of BIUB and Antibiotic Use
There were 2,144 deliveries in the study period. Total 100 cases diagnosed with CAM were excluded. We also excluded 14 patients with BIUB who received antibiotics that were not given in accordance to our protocol. As a result, among 2,144 deliveries in the study period, we identified 758 women diagnosed with PPH (≥1,000 mL), of which 80 were treated with BIUB for hemostasis. There were 678 cases of PPH without BIUB and investigated as a control group. The BIUB group was further divided into 32 (40.0%), 28 (35.0%), and 20 (25.0%) patients in the VD, el-CD, and em-CD groups, respectively; the corresponding numbers in the non-BIUB group were 243 (35.8%), 235 (34.7%), and 200 (29.5%), respectively.

Patient characteristics are summarized in Table 1. The groups did not differ significantly in terms of baseline characteristics except for median maternal age (BIUB group: 36 vs. non-BIUB group: 35, p = 0.049), median maternal body mass index (BIUB group: 24.2 vs. non-BIUB group: 24.9, p = 0.0058), and frequency of placental abnormalities (BIUB group: 33.3% vs. non-BIUB group: 15.9%, p = 0.0047).

The clinical outcomes of the BIUB group are shown in Table 2. Almost 90% of patients received prophylactic ampicillin (ABPC) (2 g) or cefazolin (1 g), while the remaining 10% received gentamicin, clindamycin, sulbactam/ABPC (SBT), or ceftriaxone. This is because the 10% were suspected of having penicillin allergy or were chosen by the clinician’s preference. However, all antibiotic drugs were administered as a single dose. The uterus preservation rate was 92.5% (74/80). Median total blood loss, transfusion rate, and endometritis rate among the VD, el-CD, and em-CD groups are shown in Table 3. We observed no significant difference in the rate of postpartum endometritis between the BIUB and non-BIUB groups in either the VD group (3.1% [1/32] vs. 2.1% [5/243], p = 0.33), the el-CD group (7.1% [2/28] vs. 3.8% [9/235], p = 0.33), or the em-CD group (10.0% [2/20] vs. 12.5% [25/200], p = 1.00).

Supplementary Materials S2 and S3 (available online only) show the results of the analysis for all patients who delivered at our institution during the study period, including non-PPH patients with blood loss of 1,000 mL or less. As was the case with PPH patients, there was no significant difference in the rate of endometritis between the BIUB and non-BIUB groups.

Literature Review
As outlined in Supplementary Materials S1 and S4 (available online only), the electronic literature search revealed 152 articles, and the studies referring to prophylactic antibiotic use in BIUB placement are shown in Table 4 (27 articles). The prophylactic antibiotics used included cephradine (one article), cephalozin (two articles), a combination of multiple antibiotics (four articles), and broad-spectrum antibiotics (nine articles). Total 10 of the articles did not provide details about the kind of antibiotics used.

Prophylactic antibiotics were reportedly given as a single dose in one article and as multiple doses in 17 articles, but no details about dosing frequency were reported in nine articles. The dose and duration of antibiotic use also varied according to the institution. Finally, although 152 articles described the use of BIUBs, none of them investigated or discussed the use of antibiotic prophylaxis protocols.
The key findings of our study are that a single dose of prophylactic antibiotics in VD cases, and no additional antibiotics in CD cases, for BIUB placement might be effective and sufficient to prevent postpartum endometritis related to BIUB placement. Moreover, our literature review revealed that our study is the first to evaluate the risk of endometritis in BIUB placement and multiple doses of antibiotics were administered in approximately 65% of articles during BIUB placement.

Ever since its effectiveness was confirmed, BIUB has been widely incorporated as a standard option for the conservative management of PPH. As BIUB utilization continues to increase, obstetricians must pay greater attention to the associated risks and complications. Previous studies have reported several complications and adverse events associated with BIUB. They include uterine perforation or cervical trauma during balloon placement, failure of tamponade due to a

Discussion

The key findings of our study are that a single dose of prophylactic antibiotics in VD cases, and no additional antibiotics in CD cases, for BIUB placement might be effective and sufficient to prevent postpartum endometritis related to BIUB placement. Moreover, our literature review revealed that our study is the first to evaluate the risk of endometritis in BIUB placement and multiple doses of antibiotics were administered in approximately 65% of articles during BIUB placement.

Ever since its effectiveness was confirmed, BIUB has been widely incorporated as a standard option for the conservative management of PPH. As BIUB utilization continues to increase, obstetricians must pay greater attention to the associated risks and complications. Previous studies have reported several complications and adverse events associated with BIUB. They include uterine perforation or cervical trauma during balloon placement, failure of tamponade due to a

Table 1 Demographic characteristics for women with or without Bakri intrauterine balloon (cases of blood loss ≥1,000 mL)

| BIUB group | non-BIUB group | p-Value |
|------------|----------------|---------|
| Number of cases | 80 | 678 | |
| Maternal age (y) | Median (range) 36 (25–44) | 35 (18–53) | 0.049* |
| Maternal body mass index at delivery | Median (range) 24.2 (18.5–36.7) | 24.9 (16.5–50.7) | 0.0058a |
| Parity, n (%) | Primipara (0) | 31 (38.8) | 277 (40.9) | 0.81c |
| | Multipara (1 ≤) | 77 (92.2) | 401 (59.1) | |
| Length of pregnancy at delivery (wk) | Median (range) 38 (24–41) | 38 (29–42) | 0.54a |
| | Preterm delivery <37 weeks, n (%) | 16 (20.0) | 126 (18.6) | 0.76c |
| | Vaginal delivery | 32 (40.0) | 243 (35.8) | 0.46c |
| | Elective cesarean delivery | 28 (35.0) | 235 (34.7) | 1.00c |
| | Emergency cesarean delivery | 20 (25.0) | 200 (29.5) | 0.44c |
| | GBS-positive, n (%) | 7 (8.8) | 102 (15.0) | 0.18c |
| | PROM, n (%) | 8 (10.0) | 55 (8.1) | 0.52c |
| | Placement of an IPC, n (%) | 5 (6.3) | 47 (6.9) | 1.00c |
| | Manual removal of placenta, n (%) | 7 (8.8) | 29 (4.3) | 0.091c |
| Indication for CD, n (%) | Previous CD and myomectomy | 12 (25.0) | 163 (37.5) | 0.11c |
| | Non-reassuring FHR | 5 (10.4) | 52 (11.9) | 1.00c |
| | Labor arrest and induction failure | 4 (8.3) | 70 (16.1) | 0.21c |
| | Placental abnormalitiesb | 16 (33.3) | 69 (15.9) | 0.0047c |
| | Abnormalities of UCI | 0 (0) | 5 (1.1) | 1.00c |
| | Multiple pregnancy | 3 (6.3) | 17 (3.9) | 0.44c |
| | Malpresentation | 3 (6.3) | 29 (6.7) | 1.00c |
| | Others | 5 (10.4) | 30 (6.9) | 0.38c |
| Additional treatment | Blood transfusion, n (%) | 50 (62.5) | |
| | Interventional radiology, n (%) | 11 (13.8) | |
| | Uterine compression suture, n (%) | 6 (7.5) | |
| | Hysterectomy, n (%) | 6 (7.5) | |
| Complications | Failure of tamponade, n (%) | 2 (2.5) | |
| | Endometritis, n (%) | 5 (6.3) | |
| | Uterine perforation by BIUB placement, n (%) | 0 (0) | |
| | Cervical trauma by BIUB placement, n (%) | 0 (0) | |
| Type of antibiotics used as prophylaxis, n (%) | ABPC 2 g | 41 (51.3) | |
| | CEZ 1 g | 32 (40.0) | |
| | ABPC 2 g + GM 200 mg | 2 (2.5) | |
| | ABPC 2 g + CLDM 600 mg | 1 (1.2) | |
| | ABPC 2 g + CLDM 600 mg + GM 200 mg | 1 (1.2) | |
| | GM 240 mg + CLDM 600 mg | 1 (1.2) | |
| | SBT/ABPC 1,500 mg | 1 (1.2) | |
| | CTRX 1 g | 1 (1.2) | |

Abbreviations: BIUB, Bakri intrauterine balloon; GBS, Group B Streptococcus; FHR, fetal heart rate; IPC, intrauterine pressure catheter; PROM, premature rupture of the membranes; UCI, umbilical cord insertion. *p value from t-test of differences between BIUB and non-BIUB groups. †Placenta previa and low-lying placenta cases. ‡p value from Fisher’s exact test of differences between BIUB and non-BIUB groups.
broken balloon or inadequate inflation, uterine rupture due to excessive inflation, and infection.\(^{18}\)

The rates of many of these complications may be reduced by using ultrasound guidance for device insertion: the Matsubara–Nelaton’s method\(^{21,22}\) and the tamponade test.\(^{23,24}\) However, it is unclear whether these procedures lower infection rates. Considering infections such as postpartum endometritis complication of BIUB,\(^{14,15}\) it is surprising that there has been little discussion of the rate of infection or the use of prophylactic antibiotics in the literature.

According to our review of the effectiveness of prophylactic antibiotics,\(^{17}\) (65.4\%) out of 27 publications used multiple doses of antibiotics. We found that the type, frequency, dose, and duration of antibiotics varied according to the institution, and no previous study had compared antibiotic regimens for preventing endometritis. Although we wanted to investigate the rate of endometritis according to antibiotic regimen, only 11 (40.7\%) out of 27 studies mentioned the rate of endometritis and none had investigated the rate of endometritis according to antibiotic regimens for preventing endometritis. Although it is conceivable that the rate of endometritis in patients receiving BIUBs may not increase without prophylactic antibi-otic use, we were at least able to show that a single-dose of prophylactic antibiotics might be effective in preventing an infection.

A major strength of the present study is that we formally evaluated both the risk of endometritis associated with BIUB placement, and the effectiveness of prophylactic antibiotic therapy. This was then supported with data from a literature review of antibiotic use for BIUB placement. Second, we found that multiple doses of antibiotics were administered in approximately 65\% of articles. We believe that our data are useful for reducing the use of antibiotics without an increased rate of infection.

Our study included several limitations. One is that this was only a single-center retrospective study with small sample size; unmeasured bias may exist in the analysis. To ensure the safe and effective use of BIUBs for PPH, larger studies are needed. Second, we could not match the patient characteristics between BIUB and non-BIUB cases well. Small sample size did not allow us to perform propensity score matching; thus, we selected the PPH cases to reduce the bias of hemorrhage. We are aware this is not an ideal method; however, we believe it is an acceptable method.

Third, we could not investigate the risk of endometritis in cases without antibiotic administration. To clearly show that our antibiotics protocol is sufficient to prevent infection, we should conduct the study as follows: comparing two study groups in which one receives antibiotics and the other does not receive antibiotics. In the CD groups, we administered antibiotics preoperatively, and when blood loss exceeded 1,500 mL as part of the routine strategy to prevent surgical site infections, according to the ACOG recommendations.\(^{26,27}\) Although it is surprising that the rate of endometritis in patients receiving BIUBs may not increase without prophylactic antibiotic use, we were at least able to show that a single-dose of prophylactic antibiotics might be effective in preventing an infection.

### Table 3 Comparison of blood loss, blood transfusion rate, and endometritis rate by mode of delivery (cases of blood loss \(\geq 1,000\) mL)

|                  | BIUB group | non-BIUB group | \(p\)-Value |
|------------------|------------|----------------|------------|
| **Number of cases** | 80         | 678            |            |
| **Median of total blood loss, mL. (range)** |            |                |            |
| Vaginal delivery | 2,233 (1,025–7,970) | 1,255 (1,000–7,400) | 0.0001\(^a\) |
| Elective cesarean delivery | 2,250 (1,081–3612) | 1,255 (1,000–8,470) | 0.0001\(^a\) |
| Emergency cesarean delivery | 2,252 (1,012–4,500) | 1,250 (1,000–8,972) | 0.15\(^a\) |
| **Blood transfusion, \(n\) (%)** |            |                |            |
| Vaginal delivery | 19/32 (59.4) | 26/243 (10.7) | \(<0.0001\)^b |
| Elective cesarean delivery | 18/28 (64.3) | 18/235 (7.7) | \(<0.0001\)^b |
| Emergency cesarean delivery | 13/20 (65.0) | 32/200 (16.0) | \(<0.0001\)^b |
| **Endometritis, \(n\) (%)** |            |                |            |
| Vaginal delivery | 1/32 (3.1) | 5/243 (2.1) | 0.53\(^b\) |
| Elective cesarean delivery | 2/28 (7.1) | 9/235 (3.8) | 0.33\(^b\) |
| Emergency cesarean delivery | 2/20 (10.0) | 25/200 (12.5) | 1.00\(^b\) |

Abbreviation: BIUB, Bakri intrauterine balloon.

\(^{a}\) \(p\)-value from \(t\)-test of differences of blood loss between BIUB and non-BIUB groups.

\(^{b}\) \(p\)-value from Fisher’s exact test of differences in the rate of blood transfusion and endometritis between BIUB and non-BIUB groups.
Table 4: Summary of the literature regarding prophylactic antibiotic use for BIUB placement

| Author Reference | Year   | Study design | No.  | Type of antibiotics | Dose and frequency          | Duration of antibiotic                  | The rate of infection n (%) |
|------------------|--------|--------------|------|---------------------|----------------------------|-----------------------------------------|----------------------------|
| Wang D (S1)      | 2018   | Prospective  | 407  | NR                  | NR                         | NR                                      | 0 (0)                      |
| Zeng C (S2)      | 2017   | Retrospective| 27   | BS                  | MD                        | 48 hours after delivery               | NR                        |
| Mathur M (S3)    | 2018   | Retrospective| 49   | NR                  | MD                        | During balloon placement              | NR                        |
| Soyama H (S4)    | 2017   | Retrospective| 50   | NR                  | Twice                     | At the beginning of CD, 12 hours after CD | 0 (0)                    |
| Darwish AM (S5)  | 2018   | RCT          | 33   | CED 1 g             | Every 12 hours, DIV (MD)  | 24 hours after balloon placement      | 0 (0)                     |
| Abraham C (S6)   | 2017   | Case report  | 1    | NR                  | MD                        | During balloon placement              | 0 (0)                     |
| Revert M (S7)    | 2017   | Prospective  | 226  | AMPC/CVA + GM       | MD                        | 48 hours after delivery               | 1 (0.44)                  |
| Cho HY (S8)      | 2015   | Retrospective| 64   | CEZ 1 g             | Every 12 hours, DIV (MD)  | During balloon placement              | NR                        |
| Vintejoux E (S9) | 2015   | Retrospective| 36   | NR                  | Single-dose               | --                                     | NR                        |
| Alkis I (S10)    | 2015   | Retrospective| 47   | BS                  | NR                        | NR                                     | NR                        |
| Cengiz H (S11)   | 2015   | Case report  | 1    | BS                  | MD                        | During balloon placement              | NR                        |
| Kaya B (S12)     | 2014   | Prospective  | 45   | CEZ 1 g             | MD                        | NR                                     | 0 (0)                     |
| Beckmann MM (S13)| 2014   | RCT          | 25   | CEZ 1 g             | DIV (Twice)               | At the delivery and 12 hours after delivery | 0 (0)                    |
| Kawak SB (S14)   | 2013   | Prospective  | 7    | BS                  | NR                        | NR                                     | NR                        |
| Vrachnis N (S15)| 2013   | Retrospective| 18   | NR                  | NR                        | NR                                     | 0 (0)                     |
| Patacchiola F (S16)| 2012  | Retrospective| 16   | BS                  | NR                        | NR                                     | 0 (0)                     |
| Laas E (S17)     | 2012   | Retrospective| 43   | AMPC/CVA + GM       | MD                        | 48 hours after delivery               | 1 (2.3)                   |
| Karateke A (14)  | 2012   | Case report  | 1    | NR                  | MD                        | During balloon placement (26 hour)    | NR                        |
| Diemert A (S18)  | 2012   | Retrospective| 20   | BS                  | MD                        | During balloon placement (24 hour)    | 0 (0)                     |
| Khalil M (S19)   | 2011   | RCT          | 50   | BS                  | MD                        | 48 hours after delivery               | NR                        |
| Arduini M (S20)  | 2010   | Retrospective| 9    | ABPC/SBT 3 g        | Every 12 hours, DIV (MD)  | NR                                     | NR                        |
| Georgiou C (S21)| 2010   | Case study   | 2    | CEZ + CEX + MNZ     | *                        | CEZ: 24 hours, CEX + MNZ: 4 days      | NR                        |
| Majid H (S22)    | 2009   | Case report  | 1    | TAZ/PIPC + OAT      | MD                        | NR                                     | NR                        |
| Vithhala S (S23)| 2009   | Retrospective| 15   | BS                  | NR                        | NR                                     | NR                        |
| Nelson WL (S24)  | 2007   | Retrospective| 5    | NR                  | MD                        | During balloon placement              | NR                        |
| Tahaoglu AE (S25)| 2017   | Retrospective| 42   | NR                  | NR                        | NR                                     | NR                        |
| Agrawal R (S26)  | 2011   | Case report  | 1    | NR                  | NR                        | NR                                     | NR                        |

Abbreviations: ABPC/SBT, ampicillin/sulbactam; BIUB, Bakri intrauterine balloon; BS, Broad-spectrum; CD, cesarean delivery; CED, cephradine; CEX, cephalaxin; CEZ, cephalizin; CVA/AMPC, clavulanic acid/amoxicillin; DIV, drip intravenous; GM, gentamicin; MD, multiple-dose; MNZ, metronidazole; No., number of cases; NR, not reported; OA, oral administration; OAT, oral antibiotics; RCT, randomized control trial; TAZ/PIPC, tazobactam/piperacillin.

*CEZ 1 g, every 12 hours, DIV + CEX 1500 mg/day, OA + MNZ 1,500 mg/day, OA.
not receive antibiotics in the prospective or randomized control study. Fourth, the relationship between rate of infection and details of antibiotics (regimen and administered cycle) was not available in most previous studies making regimen-specific discussion not feasible.

In conclusion, we found no association between endometritis and the placement of a Bakri Balloon for PPH among different modes of delivery. We also conclude that antibiotic prophylaxis may be helpful in preventing this infection. However, more robust studies like randomized control trials are needed to clarify the link between the use of antibiotics as prophylaxis for procedures, such as a Bakri balloon placement and prevention of infection.

Authors’ Contribution
Y.N., S.M., Y.K., M.E., A.K., and T.T. contributed to study conception and design, data collection, and drafting of the manuscript. M.E., T.T., and T.K. investigated the articles identified in the literature search. A.K. performed an extensive revision of the revised manuscript. T.K. conceived the study, provided general supervision, helped draft the manuscript, and gave final approval for publication of the manuscript. All authors read and approved the final version of the manuscript.

Conflicts of Interest
The authors declare no conflicts of interest or relevant financial relationships associated with the present study.

Acknowledgment
The authors thank H. Abe and K. Sakiyama for administrative assistance in the preparation of this manuscript.

References
1 American College of Obstetrics. Committee on practice bulletin-obstetrics. practice bulletin no. 183: postpartum hemorrhage. Obstet Gynecol 2017;130:e168–e186
2 Ishii T, Sawada K, Koyama S, et al. Balloon tamponade during cesarean section is useful for severe post-partum hemorrhage due to placenta previa. J Obstet Gynaecol Res 2012;38(01):102–107
3 Kayem G, Kurinczuk JJ, Alfirevic Z, Spark P, Brocklehurst P, Knight M; U.K. Obstetric Surveillance System (UKOSS). Uterine compression sutures for the management of severe postpartum hemorrhage. Obstet Gynecol 2011;117(01):14–20
4 Lo A, St Marie P, Yadav P, Belisle E, Markenson G. The impact of Bakri balloon tamponade on the rate of postpartum hysterectomy for uterine atony. J Matern Fetal Neonatal Med 2017;30(10):1163–1166
5 Nishikawa A, Matsuzaki S, Mimura K, Kanagawa T, Kimura T. Short interpregnancy interval after B-Lynch uterine compression suture: a case report. Clin Exp Obstet Gynecol 2016;43(03):434–436
6 Bakri YN. Uterine tamponade-drain for hemorrhage secondary to placenta previa-accreta. Int J Gynaecol Obstet 1992;37(04):302–303
7 Marcovici I, Scocca B. Postpartum hemorrhage and intrauterine balloon tamponade. A report of three cases. J Reprod Med 1999;44(02):122–126
8 Goldrath MH. Uterine tamponade for the control of acute uterine bleeding. Am J Obstet Gynecol 1983;147(08):869–872
9 Katesmark M, Brown R, Raju KS. Successful use of a Sengstaken-Blakemore tube to control massive postpartum haemorrhage. Br J Obstet Gynaecol 1994;101(03):259–260
10 Johanson R, Kumar M, Obhrai M, Young P. Management of massive postpartum haemorrhage: use of a hydrostatic balloon catheter to avoid laparotomy. BJOG 2001;108(04):420–422
11 Akhter S, Begum MR, Kabir Z, Rashid M, Laila TR, Zabeen F. Use of a condom to control massive postpartum hemorrhage. MedGenMed 2003;05(03):38
12 Aibar L, Aguilar MT, Puertas A, Valverde M. Bakri balloon for the management of postpartum hemorrhage. Acta Obstet Gynecol Scand 2013;92(04):465–467
13 Bakri YN, Amri A, Abdul Jabbar F. Tamponade-balloon for obstetrical bleeding. Int J Gynaecol Obstet 2001;74(02):139–142
14 Karateke A, Kücükbaş M, Sozen H, Namazov A, Cakir S, Akdemir Y. Fertility sparing surgery on placenta invasion anomalies and placenta previa. Iran J Reprod Med 2012;10(03):271–274
15 Georgiou C. Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG 2009;116(06):748–757
16 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36(05):309–332
17 Matsuzaki S, Matsuzaki S, Ueda Y, et al. A case report and literature review of mid trimester termination of pregnancy complicated by placenta previa and placenta accreta. AJR Rep 2015;05(01):e6–e11
18 Matsuzaki S, Yoshino K, Endo M, Kagigano A, Takuchi T, Kimura T. Conservative management of placenta percreta. Int J Gynaecol Obstet 2018;140(03):299–306
19 Rocher G, Panel P, Rollin I, et al. Massive hemoperitoneum due to uterine perforation by the Bakri Balloon, during the treatment of postpartum hemorrhage. J Gynecol Obstet Hum Reprod 2019;48(01):75–76
20 Leparco S, Viot A, Benachi A, Deffieux X. Migration of Bakri balloon through an unsuspected uterine perforation during the treatment of secondary postpartum hemorrhage. Am J Obstet Gynecol 2013;208(06):e6–e7
21 Matsubara S. An easy insertion procedure of Bakri balloon during cesarean section for placenta previa: use of Nelaton rubber catheter. Arch Gynecol Obstet 2014;290(04):613–614
22 Matsubara S, Takahashi H, Baba Y, Usui R. Inserting the Bakri balloon during cesarean section in patients with a narrow cervix: Nelaton method (Matsubara). Acta Obstet Gynecol Scand 2015;94(10):1147–1148
23 Condous GS, Arulkumaran S, Symonds I, Chapman R, Sinha A, Razvi K. The “tamponade test” in the management of massive postpartum hemorrhage. Obstet Gynecol 2003;101(04):767–772
24 Frenzel D, Condous GS, Papageorghiou AT, McWhinney NA. The use of the “tamponade test” to stop massive obstetric haemorrhage in placenta accreta. BJOG 2005;112(05):676–677
25 World Health Organization. Antimicrobial resistance. (Updated: Feb 2018.) Accessed Jan 1, 2019. Available at: https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance#
26 American College of Obstetrics. Committee on practice bulletin-obstetrics. ACOG practice bulletin no. 199: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol 2018;132: e103–e119
27 Swoboda SM, Merz C, Kostuik J, Trenlter B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg 1996;131(11):1165–1171, discussion 1171–1172